Kyowa Hakko Kirin Co., Limited

Kyowa Hakko Kogyo Co., Ltd.

Naoki Seno

Hiroshi Kase

Shizuo Shiozaki

Minoru Kobayashi

Akihisa Mori

Junya Kase

Takako Kadowaki

Dayao Zhao

Takado Kadowaki

Junya PharmaResCenter Kase

Shizuo PharmaResCenter Shiozaki

The present invention provides pharmaceutical compositions, which are useful for treatment of depression and the like, and which comprises a compound having an adenosine Areceptor antagonistic activity such as (E)-8-(3,4-dimethoxystyryl)-1,3-diethyl-7-methyl-3,7-dihydro-1H-purine-2,6-dione or a pharmaceutically acceptable salt thereof and an antidepressant drug (for example, a tricyclic antidepressant, a tetracyclic antidepressant, a selective serotonin reuptake inhibitor, a selective noradrenalin reuptake inhibitor, a dopamine reuptake inhibitor, a serotonin-noradrenalin reuptake inhibitor, monoamine oxidase inhibitor, a 5-HTantagonist or the like), and the like.

Pharmaceutical composition containing KW-6002 and fluoxetine or paroxentine

Anxiety disorders, such as panic disorder, agoraphobia, obsessive-compulsive disorder, social phobia, post-traumatic stress disorder, generalized anxiety disorder, specific phobia, or the like, are treated by administering an effective amount of at least one adenosine Areceptor antagonist to a patient in need thereof, optionally in combination with an anxiolytic(s) other than the adenosine Areceptor antagonist.

Method of treating an anxiety disorder

Pharmaceutical composition

The present invention provides pharmaceutical compositions, which are useful for treatment of depression and the like, and which comprises a compound having an adenosine Areceptor antagonistic activity such as (E)-8-(3,4-dimethoxystyryl)-1,3-diethyl-7-methyl-3,7-dihydro-1H-purine-2,6-dione or a pharmaceutically acceptable salt thereof and an antidepressant drug (for example, a tricyclic antidepressant, a tetracyclic antidepressant, a selective serotonin reuptake inhibitor, a selective noradrenalin reuptake inhibitor, a dopamine reuptake inhibitor, a serotonin-noradrenalin reuptake inhibitor, a monoamine oxidase inhibitor, a 5-HTantagonist or the like), and the like.

For example, an agent for preventing and/or treating movement disorder comprising, as an active ingredient, a triazolopyrimidine derivative having an adenosine Areceptor antagonistic action, which is represented by the following formula (I): (wherein Rrepresents substituted or unsubstituted aryl or a substituted or unsubstituted heterocyclic group, Rrepresents a hydrogen atom, or the like, Rrepresents &#x2014;WR, or the like, and Qrepresents a hydrogen atom or 3,4-dimethoxybenzyl), or a pharmaceutically acceptable salt thereof, and the like are provided.

Agent for preventing and/or treating movement disorder

The present invention provides methods of treating restless legs syndrome or related disorders, comprising administering an effective amount of at least one adenosine Areceptor antagonist to a patient in need thereof. More preferably the adenosine Areceptor antagonist is a xanthine derivative or a pharmaceutically acceptable salt thereof.

Growing community of inventors

Moriya, Japan

Naoki Seno